GlassScriptPhysician profile
Amy N Brett
NPI 1437898921
$2,587.70
in general payments reported to CMS, 2019-2025
42 companies · $816 in 2025
The $816 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $515 · 2023: $473 · 2024: $783 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,972 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,972.28 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $190.82 | 2023-2025 | Jakafi, Monjuvi, Niktimvo |
| Sanofi-Aventis U.S. LLC | $167.98 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $150.48 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $144.63 | 2023-2024 | Fruzaqla, Alunbrig, Iclusig |
| Astrazeneca Pharmaceuticals LP | $144.20 | 2022-2025 | Enhertu, Imfinzi |
| Janssen Biotech, INC. | $140.68 | 2022-2025 | Darzalex, Tecvayli, Carvykti |
| Genentech USA, INC. | $139.63 | 2024-2025 | Tecentriq, Polivy, Alecensa |
| Gilead Sciences, INC. | $120.37 | 2023-2025 | Trodelvy |
| Pfizer INC. | $109.43 | 2023-2025 | |
| Abbvie INC. | $104.46 | 2022-2024 | |
| Genzyme Corporation | $92.02 | 2022-2025 | |
| Genmab U.S., INC. | $85.71 | 2023-2025 | Epkinly, Tivdak |
| Myovant Sciences INC. | $81.49 | 2022 | |
| Merck Sharp & Dohme LLC | $74.92 | 2022-2025 | Keytruda, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $60.46 | 2022-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $58.10 | 2023-2024 | Verzenio, Jaypirca |
| Kyowa Kirin, INC. | $55.40 | 2022-2025 | Poteligeo |
| E.R. Squibb & Sons, L.L.C. | $51.74 | 2022-2025 | Opdivo |
| Kite Pharma, INC. | $47.29 | 2024-2025 | Yescarta |
| Ipsen Biopharmaceuticals, INC | $46.54 | 2022-2025 | Onivyde |
| Pharmacosmos Therapeutics INC. | $44.89 | 2023-2024 | Monoferric |
| Jazz Pharmaceuticals INC. | $44.39 | 2024-2025 | |
| Eisai INC. | $42.53 | 2022-2025 | |
| Seagen INC. | $35.36 | 2022-2023 | Padcev |
| Morphosys, US INC. | $33.11 | 2022-2023 | Monjuvi |
| Astellas Pharma US INC | $29.24 | 2022-2023 | Xospata |
| Beigene USA, INC. | $28.38 | 2022 | |
| Sumitomo Pharma America, INC. | $21.63 | 2023 | Orgovyx |
| Alnylam Pharmaceuticals INC. | $21.16 | 2022 | |
| Stemline Therapeutics INC. | $20.76 | 2025 | Orserdu |
| Aveo Pharmaceuticals, INC. | $20.34 | 2023 | Fotivda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.61 | 2024 | |
| Springworks Therapeutics, INC. | $19.38 | 2024 | Ogsiveo |
| Apellis Pharmaceuticals, INC. | $19.18 | 2022 | |
| Recordati_rare_diseases_inc. | $18.73 | 2024 | Sylvant |
| Regeneron Healthcare Solutions, INC. | $18.51 | 2022 | |
| Deciphera Pharmaceuticals INC. | $17.69 | 2025 | Romvimza, Qinlock |
| Mirati Therapeutics, INC. | $16.29 | 2023 | Krazati |
| Array Biopharma INC | $14.46 | 2024 | Braftovi, Tukysa, Mektovi |
| Alexion Pharmaceuticals, INC. | $13.91 | 2025 | Ultomiris |
| Taiho Oncology, INC. | $11.79 | 2022 | |
| Organon LLC | $10.01 | 2023 | Ontruzant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Brett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.